Funding for Phase 1 & 2

In February 2019, a scientific development program was initiated and a grant proposal is being expected for submission in 2019/2020.




WPD102 has not been submitted for FDA or EMA approval so far.



Additional Indications

Wake Forest Baptist Medical Center
Recognized, fully integrated academic medical center and health system located in Winston-Salem, North Carolina, USA.

North Carolina Baptist Hospital
Operates inpatient hospitals, community health centers, health maintenance organization, primary care centers and teaching hospital as a subsidiary of Wake Forest Baptist Medical Center.

Clinic of Ophthalmology and Oncology Ophthalmology Jagiellonian University
In Kraków, Poland, drug development

WPD Pharmaceuticals
Co-development partner


Preclinical Development

WPD102 is currently in preclinical development and based on the data obtained from in vitro studies using cancer cell lines, we see significant potential for WPD102 for the treatment of UV in humans. A Phase I clinical trial is expected to begin in 2021-22.



Subsequent Studies

Primary focus on primary UV and subsequently on liver UV lesions and related cancers with high overexpression of IL-13RA2.


No Curative Options

With no other curative options available, we believe WPD102 may have the potential for accelerated approval as a safe and effective therapy for primary UV. Moreover, other types of cancer that will be confirmed as IL-13RA2, could potentially be explored as WPD102 targets.